Evidence map›Paper›PMID 35983955›Full record

ArticleDiabetes2022

TBK1-mTOR Signaling Attenuates Obesity-Linked Hyperglycemia and Insulin Resistance.

Cagri Bodur, Dubek Kazyken, Kezhen Huang, Aaron Seth Tooley, Kae Won Cho, Tammy M Barnes, Carey N Lumeng, Martin G Myers, Diane C Fingar

Open access · greenAbstract read
In one paragraph

Article in Diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. mTORC1 in energy expenditure: consequences for obesity.Nature reviews. Endocrinology · 2024
    Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Cagri BodurDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI.
Dubek KazykenDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI.
Kezhen HuangDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI.
Aaron Seth TooleyDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI.
Kae Won ChoDepartment of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, MI.
Tammy M BarnesDepartment of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, MI.
Carey N LumengDepartment of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0003-0303-6204
Martin G MyersDepartment of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0001-9468-2046
Diane C FingarDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0002-9801-1482
University of Michigan · US

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kanakadurga Singer · 2010 to 2026
$20.3M
Cellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6M
Direct regulation of mTORC1 and mTORC2 by the IKK-related kinases TBK1 and IKKϵR01DK103877 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FINGAR, DIANE C. · 2014 to 2017
$838k
Integration of innate immune function and metabolism by the TBK1-mTOR axisR56DK126328 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FINGAR, DIANE C. · 2020 to 2020
$156k
NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK089503NIDDK NIH HHS R01 DK103877NIDDK NIH HHS R56 DK126328NIGMS NIH HHS T32 GM145304
6 · The paper itself

Abstract

The innate immune kinase TBK1 (TANK-binding kinase 1) responds to microbial-derived signals to initiate responses against viral and bacterial pathogens. More recent work implicates TBK1 in metabolism and tumorigenesis. The kinase mTOR (mechanistic target of rapamycin) integrates diverse environmental cues to control fundamental cellular processes. Our prior work demonstrated in cells that TBK1 phosphorylates mTOR (on S2159) to increase mTORC1 and mTORC2 catalytic activity and signaling. Here we investigate a role for TBK1-mTOR signaling in control of glucose metabolism in vivo. We find that mice with diet-induced obesity (DIO) but not lean mice bearing a whole-body "TBK1-resistant" Mtor S2159A knock-in allele (MtorA/A) display exacerbated hyperglycemia and systemic insulin resistance with no change in energy balance. Mechanistically, Mtor S2159A knock-in in DIO mice reduces mTORC1 and mTORC2 signaling in response to insulin and innate immune agonists, reduces anti-inflammatory gene expression in adipose tissue, and blunts anti-inflammatory macrophage M2 polarization, phenotypes shared by mice with tissue-specific inactivation of TBK1 or mTOR complexes. Tissues from DIO mice display elevated TBK1 activity and mTOR S2159 phosphorylation relative to lean mice. We propose a model whereby obesity-associated signals increase TBK1 activity and mTOR phosphorylation, which boost mTORC1 and mTORC2 signaling in parallel to the insulin pathway, thereby attenuating insulin resistance to improve glycemic control during diet-induced obesity.

Indexed as

HyperglycemiaInsulin ResistanceAnimalsGlucoseInsulinMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MiceMice, ObeseMultiprotein ComplexesObesityProtein Serine-Threonine KinasesSirolimusTOR Serine-Threonine KinasesGlucoseInsulinMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2Multiprotein ComplexesProtein Serine-Threonine KinasesSirolimusTbk1 protein, mouseTOR Serine-Threonine Kinases

Identifiers

PMID35983955
PMCPMC9630091
OpenAlexW4292300298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.